지니너스
Financials
Valuation Metrics
지니너스's Market Cap is ₩452B. At end of 2025 it was ₩1379B. Ranked #1779 of 2,405 in KR market (top 74%), #1087 of 1,627 on KOSDAQ (top 67%), #190 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 45.18B KRW | KR#1,779/2,405 Sec#190/231 |
| Revenue | 11.28B KRW | KR#2,263/2,405 Sec#172/231 |
| Net Income | -20.36B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 54.56B KRW | KR#2,157/2,405 Sec#192/231 |
| Net Assets | 40.68B KRW | KR#2,029/2,405 Sec#179/231 |
| Employees | 73 | KR#1,848/2,405 Sec#159/231 |
| Value | ||
| P/B | 1.11x | KR#1,606/2,405 Sec#102/231 |
| P/S | 4.01x | KR#2,099/2,405 Sec#138/231 |
| FCF Yield | -18.62% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -50.04% | KR#2,262/2,405 Sec#195/231 |
| ROA | -37.31% | KR#2,328/2,405 Sec#210/231 |
| Op. Margin | -105.77% | KR#2,289/2,405 Sec#175/231 |
| Revenue Growth | 33.88% | KR#338/2,405 Sec#35/231 |
| Financial Health | ||
| Debt Ratio | 34.13% | KR#664/2,405 Sec#77/231 |
| Total Debt | 6.76B KRW | KR#1,724/2,405 Sec#162/231 |
| FCF | -8.42B KRW | KR#1,648/2,405 Sec#140/231 |
| Cash | 13.57B KRW | KR#1,500/2,405 Sec#121/231 |
| Current Ratio | 3.11x | KR#528/2,405 Sec#75/231 |
| Performance | ||
| 1Y Return | -47.98% | KR#1,997/2,405 Sec#173/231 |
| 1M Return | -45.12% | KR#2,361/2,405 Sec#230/231 |
| From 52W High | -82.30% | KR#2,322/2,405 Sec#216/231 |
| 1Y MDD | -81.71% | KR#2,304/2,405 Sec#211/231 |
| Trading | ||
| Volume | 207,807 shares | KR#359/2,405 Sec#31/231 |
| Trading Value | 241.7M KRW | KR#1,056/2,405 Sec#118/231 |
| Foreign Own. | 3.84% | KR#1,083/2,405 Sec#98/231 |
| Per Share | ||
| EPS | -517 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,033 KRW | KR#2,296/2,405 Sec#211/231 |
Company Info
Spun off from Samsung Genome Research Institute in 2018, this bio venture specializes in genome analysis and solution development. It offers NGS-based cancer genome diagnostic solution CancerSCAN, single-cell analysis platform Celinus, and cloud-based spatial omics analysis solution SPACEINSIGHT. The company is advancing new businesses like AI-based new drug development and digital pathology-based companion diagnostic solutions, while collaborating with domestic and international pharmaceutical companies using its single-cell and spatial omics analysis technologies.